TRLV
Trulieve CannabisCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-08-06
Current thesis
Q1 showed positive net income, 59% gross margin, $100 million of adjusted EBITDA, and positive operating and free cash flow. Regulatory rescheduling and the company’s scaled footprint could improve future operating flexibility if execution follows.
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-08-07 · BMO.
What can break
Analyst coverage, consensus estimates, and target revisions are unavailable, limiting forward visibility.
Momentum
28
Value
68
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.75 · Bull $11.50 · Bear $6.25
Earnings
2026-08-07 · BMO
Data freshness
Prices
As of 2026-08-06
Fundamentals
As of 2026-08-06 • Vendor: Data Vendor v1
Scores
As of 2026-08-06 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-08-06
Investment thesis
As of 2026-08-06
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $18.18
Why
Momentum28 · Δ7d -4.3
Value68 · Δ7d -0.2
Sentiment55 · Δ7d +16.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
28
10% active weight
Current posture
7d trendSoftening
Δ7d
-4.3
Δ21d
-2.3
Value
68
40% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.4
Sentiment
55
49% active weight
Current posture
7d trendImproving
Δ7d
+16.9
Δ21d
+16.2
Why this grade
Composite grade C. Momentum 28.2 / Value 67.9 / Sentiment 54.8
Fundamentals (TTM)As of 2026-08-06
Fundamentals (TTM)
As of 2026-08-06
Market Cap
$1.73B
Beta
1.72
Shares Out
192.31M
P/E (TTM) · Derived
-14.8
P/S (TTM)
1.32
P/FCF (TTM)
11.08
Rev YoY
-3.7%
EPS YoY
-107.1%
Gross Margin
+49.6%
Op Margin
+10.9%
Net Debt
$308.09M
Current Ratio
5.26
As of 2026-08-06 • Updated nightlySource: Internal modelMethodology